Protocol Ledger

NCT03919799 · Phase II · TERMINATED

KD025 in Subjects With Diffuse Cutaneous Systemic Sclerosis

Interventional Phase II clinical trial protocol NCT03919799 sponsored by Sanofi in Immunology, Rheumatology, and Dermatology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2019-06-26 Enrollment: 36 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03919799
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)36 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03919799
Protocol FieldVerified Registry Value
NCT IdentifierNCT03919799
Consolidated Lead SponsorSanofi
Therapeutic Condition CohortImmunology, Rheumatology, and Dermatology
Clinical Trial PhasePhase II
Overall Recruitment StatusTERMINATED
Registered Enrollment36 participants (ACTUAL)
Registered Start Date2019-06-26
WhyStopped ClassificationSafety / Toxicity / Adverse Events

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Sanofi across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI